<DOC>
	<DOCNO>NCT00847678</DOCNO>
	<brief_summary>This multicenter , randomize , efficacy safety trial evaluate Mycograb® . Subjects randomize one 3 arm : 1/ Amphotericin B ( 0.7 mg/kg/d ) plus 5-flucytosine ( 100 mg /kg/d ) ; 2/ Amphotericin B plus Mycograb® ( dose 1 mg/kg via central line peripheral venous line twice daily 7 consecutive day ) ; 3/ Amphotericin B plus 5-flucytosine plus Mycograb® ( dose 1 mg/kg via central line peripheral venous line twice daily 7 consecutive day ) . After 2 week , patient switch fluconazole 400 mg/d 8 week 200 mg/d thereafter . The total duration study approximately 24 month</brief_summary>
	<brief_title>Efficacy Safety Mycograb Adjunctive Therapy Cryptococcal Meningitis Patients With AIDS</brief_title>
	<detailed_description />
	<mesh_term>Meningitis</mesh_term>
	<mesh_term>Meningitis , Cryptococcal</mesh_term>
	<mesh_term>Amphotericin B</mesh_term>
	<mesh_term>Liposomal amphotericin B</mesh_term>
	<mesh_term>Flucytosine</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Inclusion criterion : Male nonpregnant female &gt; 18 year old . HIVpositive unknown , acute , either first recurrent episode cryptococcal meningitis . Currently treatment , receive treatment ( &lt; 3 day ) either amphotericin B plus 5flucytosine , amphotericin B alone . Positive CSF culture Cryptococcus neoforman . Physical sign symptom meningitis , evidence one following : fever , headache , meningeal sign neurologic finding . Exclusion criterion : Excluded coma , significant medical condition . Subject opportunistic fungal infection require systemic antifungal therapy . Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2009</verification_date>
	<keyword>Cryptococcal Meningitis</keyword>
</DOC>